Evidence map›Paper›PMID 41373116›Full record

ArticleCNS neuroscience & therapeutics2025

Joint Effects of Anticholinergic Burden and Neurofilament Light on Dementia Risk: The Shanghai Aging Study.

Danyi Chi, Xiaoniu Liang, Zhenxu Xiao, Xiaowen Zhou, Qianhua Zhao, Bin Wang, Ding Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Danyi ChiDepartment of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0009-0004-8618-9349
Xiaoniu LiangInstitute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Zhenxu XiaoInstitute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Xiaowen ZhouInstitute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Qianhua ZhaoInstitute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Bin WangDepartment of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Ding DingInstitute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

Beijing Life Oasis Public Service Center CPHCF-ZLKY-2023039Huashan Hospital IIT Project HIM-2024-0272MOE Frontiers Center for Brain Science JIH2642001/028National Natural Science Foundation of China 82071200National Natural Science Foundation of China 82173599National Natural Science Foundation of China 82371429National Natural Science Foundation of China 82473701Shanghai Municipal Hospital Development Center SHDC2020CR4007Shenzhen Ye Chenghai Charity Foundation HIM-202420016STI2030-Major Projects 2021ZD0200800
6 · The paper itself

Abstract

aimsAnticholinergic drugs (ACDs) and the neurodegeneration biomarker neurofilament light chain (NfL) are associated with dementia; however, the interplay between anticholinergic drug exposure and neurodegeneration in dementia risk remains underexplored.

methodsThis prospective cohort study analyzed 1529 dementia-free adults (median follow-up 5.2 years) from the Shanghai Aging Study. Cumulative anticholinergic burden was quantified using the anticholinergic cognitive burden (ACB) scale and total standardized daily dose (TSDD) over 1 year pre-baseline. Neurofilament light chain (NfL) levels were assayed via single-molecule array (Simoa).

resultsElevated NfL (adjusted HR 1.77, 95% CI, 1.07-2.92) and TSDD exposure (HR 1.55, 1.08-2.24) were independently associated with incident dementia risk. Participants with both TSDD exposure and high NfL levels showed substantially greater cumulative dementia incidence versus those with no TSDD/low NfL (log-rank p < 0.0001; adjusted HR 2.24, 1.20-4.20). Individuals with both high TSDD and high NfL demonstrated a significantly higher dementia risk (HR 6.34, 95% CI, 1.90-21.20) compared to low-burden counterparts.

conclusionsThese findings identify plasma NfL as a critical modifier of anticholinergic-related cognitive vulnerability, providing mechanistic insights for risk stratification and supporting biomarker-guided deprescribing strategies in older adults exposed to ACDs.

Indexed as

AgingCholinergic AntagonistsDementiaNeurofilament ProteinsAgedAged, 80 and overBiomarkersChinaCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRisk FactorsBiomarkersCholinergic Antagonistsneurofilament protein LNeurofilament Proteinsanticholinergic drugscohort studydementianeurodegeneration burdenneurofilament light chainolder adults

Identifiers

PMID41373116
PMCPMC12695687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.